Deltec Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Deltec Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$331K	Hold	2,400	–	–	0.05%	192
2026 Q2	$367K	Hold	2,400	–	–	0.05%	195
2026 Q1	$299K	Hold	2,400	–	–	0.05%	181
2025 Q4	$251K	Sell	2,400 -10,100	-81%	-$862K	0.04%	184
2025 Q3	$784K	Hold	12,500	–	–	0.13%	108
2025 Q2	$282K	Hold	12,500	–	–	0.05%	159
2025 Q1	$350K	Hold	12,500	–	–	0.08%	135
2024 Q4	$150K	Buy	+12,500	New	+$196K	0.03%	152

Other funds holding PVLA

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Clio Asset Management Charlottesville, Virginia $119M AUM 1.1% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Lisanti Capital Growth New York $373M AUM 178.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

ACPLP

ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM

Deltec Asset Management's PVLA Position: Q3 2026 in Review

Deltec Asset Management held its Palvella Therapeutics (PVLA) position steady in Q3 2026 at 2,400 shares worth $331K. The position accounts for 0.05% of the portfolio, ranked #192.

Deltec Asset Management first reported a position in PVLA in Q4 2024 and has held it in 8 quarters since. The position peaked at $784K in Q3 2025. 67 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

Deltec Asset Management held 2,400 shares of Palvella Therapeutics worth $331K as of Q3 2026.
Deltec Asset Management left its Palvella Therapeutics share count unchanged in Q3 2026.
Palvella Therapeutics made up 0.05% of Deltec Asset Management's portfolio in Q3 2026, its #192 holding.
Deltec Asset Management first reported a position in Palvella Therapeutics in Q4 2024 and has held it in 8 quarters since.
Deltec Asset Management's Palvella Therapeutics position peaked at $784K in Q3 2025.
67 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on Deltec Asset Management's 13F filing for Q3 2026, filed 26 Oct 2026.